24小时热门版块排行榜    

CyRhmU.jpeg
查看: 3088  |  回复: 17
本帖产生 1 个 DRDEPI ,点击这里进行查看
当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖

hardee

铁杆木虫 (知名作家)

此草有主~

★ ★
小木虫(金币+0.5):给个红包,谢谢回帖
zhychen2008(金币+1, DRDEPI+1): 多谢提供信息 2011-09-03 16:03:22


Meantime, Eisai and Toyama Chemical Co have submitted a marketing authorisation application  for T-614 (iguratimod), an anti-rheumatic agent being jointly developed in Japan by the two companies.

T-614 is a novel disease modifying anti-rheumatic drug originally discovered by Toyama and an MAA was previously submitted in 2003. However, the application was temporarily withdrawn in 2009 in order to conduct an additional clinical study which subsequently confirmed with statistical significance the efficacy of the agent as an add-on therapy for use with the standard of care, methotrexate.

http://www.pharmatimes.com/Artic ... epsy_portfolio.aspx

只能说是先声的运气好了。。。

[ Last edited by hardee on 2011-9-1 at 15:17 ]
安得促膝,可共平生。
3楼2011-09-01 14:58:07
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

智能机器人

Robot (super robot)

我们都爱小木虫

找到一些相关的精华帖子,希望有用哦~

科研从小木虫开始,人人为我,我为人人
相关版块跳转 我要订阅楼主 ronalbeck 的主题更新
普通表情 高级回复(可上传附件)
信息提示
请填处理意见